trpv1 isg15 p16 (Boster Bio)
Boster Bio is a verified supplier 
Boster Bio manufactures this product 
94
Structured Review
Boster Bio
trpv1 isg15 p16
Trpv1 Isg15 P16, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+p16/Anti-TRPV1+Antibody/pmc13109718-142-37-34
Average 94 stars, based on 14 article reviews
Trpv1 Isg15 P16, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+p16/Anti-TRPV1+Antibody/pmc13109718-142-37-34
Average 94 stars, based on 14 article reviews
trpv1 isg15 p16 - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Membrane:Article Title: Fra-1 Inhibits Cell Growth and the Warburg Effect in Cervical Cancer Cells via STAT1 Regulation of the p53 Signaling Pathway Article Snippet: For western blot analysis of protein expression levels, HeLa cells were lysed in radioimmunoprecipitation (RIPA) buffer (CWBio, Beijing, China). .. Then 50 μg lysate was electrophoresed on 10% separation gel and transferred to a polyvinylidene difluoride membrane (HyClone Laboratories, Logan, UT, United States), which was sealed with 5% non-fat milk diluted in PBS-Tween20 for ∼2 h. Primary antibody solution was then added for incubation at 4°C for 12 h. The primary antibodies used were: anti-sirtuin 3 (SIRT3, dilution ratio: 1:500), anti-Mn superoxide dismutase 2 (MnSOD2, dilution ratio: 1:1,000), anti-isocitrate dehydrogenase 2 (IDH2, dilution ratio: 1:500), anti-liver kinase B1 (LKB1, dilution ratio: 1:500), anti-p-AMP-activated protein kinase (AMPK, dilution ratio: 1:1,000), anti-pyruvate kinase muscle isozyme 2 (PKM2, dilution ratio: 1:1,000), anti-phosphofructose kinase 1 (PFK1, dilution ratio: 1:1,000), anti-pyruvate dehydrogenase (PDH, dilution ratio: 1:1,000), anti-FOS like 1, AP-1 transcription factor subunit (FOSL1, Fra-1, Abcam, Cambridge, MA, United States, dilution ratio: 1:500), anti-signal transducer and activator of transcription 1 (STAT1, dilution ratio: 1:500), anti-c-Rel (c-Rel, dilution ratio: 1:1,000), anti-lactate dehydrogenase A (LDHA, dilution ratio: 1:1,000), anti-sirtuin 1 (SIRT1, dilution ratio: 1:500), anti- B-cell lymphoma-2 (Bcl-2, dilution ratio: 1:1,000), anti-NF kappa-B (NF-κB/p65, dilution ratio: 1:1,000, Immunoway Technology, Newark, DE, United States), anti-TP53 (p53, dilution ratio: 1:1,000), anti-cyclin-dependent kinase 4 (CDK4, dilution ratio: 1:1,000), anti-cyclin D1 (dilution ratio: 1:1,000), anti-p21 (dilution ratio: 1:1,000), anti-MAPK14/p38 (dilution ratio: 1:1,000), and anti-MDM2 (dilution ratio: 1:1,000) Incubation:Article Title: Fra-1 Inhibits Cell Growth and the Warburg Effect in Cervical Cancer Cells via STAT1 Regulation of the p53 Signaling Pathway Article Snippet: For western blot analysis of protein expression levels, HeLa cells were lysed in radioimmunoprecipitation (RIPA) buffer (CWBio, Beijing, China). .. Then 50 μg lysate was electrophoresed on 10% separation gel and transferred to a polyvinylidene difluoride membrane (HyClone Laboratories, Logan, UT, United States), which was sealed with 5% non-fat milk diluted in PBS-Tween20 for ∼2 h. Primary antibody solution was then added for incubation at 4°C for 12 h. The primary antibodies used were: anti-sirtuin 3 (SIRT3, dilution ratio: 1:500), anti-Mn superoxide dismutase 2 (MnSOD2, dilution ratio: 1:1,000), anti-isocitrate dehydrogenase 2 (IDH2, dilution ratio: 1:500), anti-liver kinase B1 (LKB1, dilution ratio: 1:500), anti-p-AMP-activated protein kinase (AMPK, dilution ratio: 1:1,000), anti-pyruvate kinase muscle isozyme 2 (PKM2, dilution ratio: 1:1,000), anti-phosphofructose kinase 1 (PFK1, dilution ratio: 1:1,000), anti-pyruvate dehydrogenase (PDH, dilution ratio: 1:1,000), anti-FOS like 1, AP-1 transcription factor subunit (FOSL1, Fra-1, Abcam, Cambridge, MA, United States, dilution ratio: 1:500), anti-signal transducer and activator of transcription 1 (STAT1, dilution ratio: 1:500), anti-c-Rel (c-Rel, dilution ratio: 1:1,000), anti-lactate dehydrogenase A (LDHA, dilution ratio: 1:1,000), anti-sirtuin 1 (SIRT1, dilution ratio: 1:500), anti- B-cell lymphoma-2 (Bcl-2, dilution ratio: 1:1,000), anti-NF kappa-B (NF-κB/p65, dilution ratio: 1:1,000, Immunoway Technology, Newark, DE, United States), anti-TP53 (p53, dilution ratio: 1:1,000), anti-cyclin-dependent kinase 4 (CDK4, dilution ratio: 1:1,000), anti-cyclin D1 (dilution ratio: 1:1,000), anti-p21 (dilution ratio: 1:1,000), anti-MAPK14/p38 (dilution ratio: 1:1,000), and anti-MDM2 (dilution ratio: 1:1,000) Western Blot:Article Title: Heterotypic neutrophil-in-tumor structure: A novel pathological feature first discovered in the tissues of OPSCC. Article Snippet: .. All antibodies with working dilution ratio, company source and catalog number are listed as follows: anti-E-cadherin (1:1000 for western blotting (WB) and 1:200 for immune fluorescent staining (IF); BD Biosciences; BD610182), anti-CDKN2A (1:1000 for WB; Abcam; ab3642), anti-EGFP (1:1000 for WB; Frontiers in Oncology 03 Invitrogen; MA1-952) anti-b-actin (1:5000 for WB; Sigma; A5441); Article Title: Heterotypic neutrophil-in-tumor structure: A novel pathological feature first discovered in the tissues of OPSCC Article Snippet: .. All antibodies with working dilution ratio, company source and catalog number are listed as follows: anti-E-cadherin (1:1000 for western blotting (WB) and 1:200 for immune fluorescent staining (IF); BD Biosciences; BD610182), anti-CDKN2A (1:1000 for WB; Abcam; ab3642), anti-EGFP (1:1000 for WB; Invitrogen; MA1-952) anti-β-actin (1:5000 for WB; Sigma; A5441); Staining:Article Title: Heterotypic neutrophil-in-tumor structure: A novel pathological feature first discovered in the tissues of OPSCC. Article Snippet: .. All antibodies with working dilution ratio, company source and catalog number are listed as follows: anti-E-cadherin (1:1000 for western blotting (WB) and 1:200 for immune fluorescent staining (IF); BD Biosciences; BD610182), anti-CDKN2A (1:1000 for WB; Abcam; ab3642), anti-EGFP (1:1000 for WB; Frontiers in Oncology 03 Invitrogen; MA1-952) anti-b-actin (1:5000 for WB; Sigma; A5441); Article Title: Heterotypic neutrophil-in-tumor structure: A novel pathological feature first discovered in the tissues of OPSCC Article Snippet: .. All antibodies with working dilution ratio, company source and catalog number are listed as follows: anti-E-cadherin (1:1000 for western blotting (WB) and 1:200 for immune fluorescent staining (IF); BD Biosciences; BD610182), anti-CDKN2A (1:1000 for WB; Abcam; ab3642), anti-EGFP (1:1000 for WB; Invitrogen; MA1-952) anti-β-actin (1:5000 for WB; Sigma; A5441); Immunohistochemistry:Article Title: Gastrin inhibits a novel, pathological colon cancer signaling pathway involving EGR1, AE2 and P-ERK Article Snippet: For immunoblotting, the antibodies below were used in this study: anti-AE2 C-terminal antibody [ 11 ], anti-cyclin D1 (sc-8396, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-P-ERK (Cell Signaling Technology, Danvers, MA, USA), anti-ERK (Cell Signaling), anti-β-catenin (sc-59737, Santa Cruz), anti-P16 (sc-81613, Santa Cruz), anti-CCKBR (sc-33221, Santa Cruz), anti-EGR1 (sc-189, Santa Cruz). .. For immunohistochemistry, antibodies anti-SLC4A2 (HPA019339, Sigma), anti-Ki67 (RMA-0129, Maixin_Bio, Fuzhou, China), |
